In patients with relapsing–remitting multiple sclerosis (RRMS), a scoring system based on new magnetic resonance imaging (MRI) active lesions, relapses and sustained disability progression after a 1-year treatment with IFNβ predicted patient disability progression over time; however, this score had not been tested in patients receiving glatiramer acetate (GA).
Objective:
The objective of this study was to evaluate whether this previous scoring system can also be applied to patients treated with GA.
Methods:
This was a prospective, longitudinal study of 151 RRMS patients treated with GA. Their scores were constructed, based on the clinical and MRI activity after 1 year of therapy. Regression analysis was performed, in order to identify the response variables.
Results:
The total possible score range was 0–3. Patients with a score of ≥ 2 and those with clinical activity (with or without MRI activity) during their first year of treatment were at increased risk of continuing with relapses and/or sustained disability in the next 2 years (odds ratio (OR): 38.8; p < 0.0001 and OR: 7.8; p < 0.009, respectively).
Conclusions:
In RRMS patients treated with GA, a combination of clinical activity measures may have prognostic value for identifying patients with disease activity in the next 2 years of therapy.
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology1993; 43: 655–661.
3.
JohnsonKPBrooksBRCohenJA. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: Results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology1995; 45: 1268–1276.
4.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing–remitting multiple sclerosis. Lancet1998; 352: 1498–1504.
5.
The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol1996; 39: 285–294.
6.
MikolDDBarkhofFChangP. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease (REGARD) study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol2008; 7: 903–914.
7.
O’ConnorPFilippiMArnasonB. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol2009; 8: 889–897.
8.
SormaniMPBruzziPComiG. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. Mult Scler2005; 11: 447–449.
9.
SormaniMPBruzziPBeckmannK. The distribution of magnetic resonance imaging response to interferon beta-1b in multiple sclerosis. J Neurol2005; 252: 1455–1458.
10.
RíoJComabellaMMontalbanX. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol2009; 5: 553–560.
11.
RudickRAPolmanCH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol2009; 8: 545–559.
12.
RioJNosCTintoréM. Defining the response to interferon-beta in relapsing–remitting multiple sclerosis patients. Ann Neurol2006; 59: 344–352.
13.
RíoJRoviraATintoréM. Relationship between MRI lesion activity and response to IFN-beta in relapsing–remitting multiple sclerosis patients. Mult Scler2008; 14: 479–484.
14.
ProsperiniLGalloVPetsasN. One-year MRI scans predict clinical response to interferon beta in multiple sclerosis. Eur J Neurol2009; 16: 1202–1209.
15.
RioJCastilloJRoviraA. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler2009; 15: 848–853.
16.
SormaniMPRioJTintoreM. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler2013; 19: 605–612.
17.
RomeoMMartinelli-BoneschiFRodegherM. Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing–remitting multiple sclerosis patients. Eur J Neurol2013; 20: 1060–1067.
18.
MezeiZBereczkiDRaczL. Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?Neuropsychiatr Dis Treat2012; 8: 465–473.
19.
MolyneuxPDMillerDHFilippiM. Visual analysis of serial T2-weighted MRI in multiple sclerosis: Intra- and interobserver reproducibility. Neuroradiology1999; 41: 882–888.
20.
MillerDHBarkhofFNautaJJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain1993; 116: 1077–1094.
21.
HeinzeGSchemperM. A solution to the problem of separation in logistic regression. Stat Med2002; 21: 2409–2419.
22.
RudickRLeeJSimonJ. Defining interferon β response status in multiple sclerosis patients. Ann Neurol2004; 56: 548–555.
23.
HavrdovaEGalettaSHutchinsonM. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the natalizumab safety and efficacy in relapsing–remitting multiple sclerosis (AFFIRM) study. Lancet Neurol2009; 8: 254–260.
24.
Freedman MS, Forrestal FG and the PRISMS study group. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon β-1a: Analysis of the PRISMS study. Mult Scler2008; 14: 1234–1241.
25.
MartaMGiovannoniG. Disease modifying drugs in multiple sclerosis: Mechanisms of action and new drugs on the horizon. CNS Neurol Disord Drug Targets2012; 11: 610–623.
26.
Dhib-JalbutS. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology2002; 58: S3–9.
27.
ComiGFilippiMWolinskyJS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol2001; 49: 290–297.
28.
BermelRAYouXFouldsP. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol2013; 73: 95–103.
